Introduction (554 words)
The ability of the body to modulate pain without the help of medical interventions is known as 2 endogenous pain inhibition. Conditioned pain modulation (CPM) is one of the well-studied 3 endogenous pain inhibitions. It involves the reduction of pain from a painful stimulus when a second 4 painful stimulus is applied distantly or heterotopically 63 . Potency of CPM is defined by percentage 5 change in pain threshold or pain rating at baseline to that during or after cold pressor. However, the 6 relationship between potency of CPM and chronic pain is inconclusive; some studies showed that 7 patients with high intensity of chronic pain displayed poorer CPM whereas 4, 17 other studies found no 8 association between pain intensity and potency of CPM 10, 14, 18 . Due to those inconsistent results and 9 not well-understood clinical implications, the clinical use of CPM, as the only test of pain inhibition in 10 quantitative sensory test (QST), is limited 62 . 11 12 Pain adaptability could be another form of pain modulation. It is assessed using a similar method to 13 that used in the measurement of the potency of CPM 15, 67 : the cold pressor test (CPT). When healthy 14 humans were subjected to a cold pressor of 2°C for five minutes, all of them reported moderate to 15 severe pain. After about two minutes, one group experienced significant pain reduction in the 16 remaining three minutes from the cold water, i.e., the pain adaptive group (PA); whereas the other 17 group experienced no changes or a slight increase in pain over time, i.e., the pain non-adaptive 18 group (PNA) 67 . This dichotomy in response to noxious stimulation was also found in another study 19 where cold water at 7°C or hot water at 47.5°C was used 15 . When CPT was used to assess CPM, all 20 tests were completed within two minutes. It is important to note that the dichotomy of PA and PNA 21 only appeared after two minutes or longer into CPT, when everyone has nearly reached their peak 22 pain. More importantly, PA reached their peak pain within a significantly shorter time than the PNA 23 did. This confirms that pain adaptability measures a form of pain inhibition that differs from CPM. It 24 Page 4 of 38
Inclusion criteria 12
Those aged between 20 and 65 years, with non-specific low back pain for more than three months 13 (diagnosed based on the Guideline from the American College of Physicians and the American Pain 14 Society 11 ) of intensity of 2 or more on a 0-10 numerical rating scale, and with adequate 15 conversational English were included in the study. 16 17 Individuals within the age range of 40 to 80 years, with adequate conversational English, with knee 18 OA diagnosed based on the guideline of the American college of Rheumatology on the criteria for 19 idiopathic osteoarthritis of the knee 3 and knee pain of intensity of 2 or more on a 0-10 numerical 20 rating scale were included. 21
Exclusion criteria 1
Participants were excluded if pregnant, intending to become pregnant or breast feeding, had 2 thermal sensitivity deficits (two Standard deviations less or more than the normal range of 3 corresponding age), had brain tumour, cancer or haemophilia, uncontrolled hypertension or had 4 injuries at the testing sites. Also, individuals with recreational drug use, excessive alcohol use, anti-5 convulsant use, anti-depressant or opioid medication use for pain, or previously diagnosed mental 6 illnesses were excluded. Since there are no standard guidelines for the diagnosis of chronic non-7 specific low back pain, the participants were selected based on the recommendations of previous 8 studies, which is by an elimination process 11, 34 . Low back pain caused by radicular neuropathy, 9 osteoporosis, surgery or previous fractures of the spine, acute trauma in the spine, inflammation, 10 malignant or autoimmune disease were not included 11 . Individuals suffering from both chronic low 11 back pain and knee osteoarthritis were excluded. 12
13
Test sites 14 The participants' thermal detection (cold and warm) and pain thresholds (cold and heat) were 15 assessed at the knees, wrists and lower back bilaterally ( Fig S1) . Their PPTs and pain ratings to 16 suprathreshold pressure stimulus (SUPRA) were also assessed bilaterally at these sites before the 17 CPTs. During the CPTs, PPT was measured at the wrist (contralateral to the most painful knee/side of 18 the lower back) and on the knee (ipsilateral). 19 20 
Outcome measures 21

Pain intensity from cold water 22
While their foot (ipsilateral to the most painful knee/side of the lower back) was immersed in cold 23 water (mixture of ice and water), participants were asked to rate their pain continuously using a 0-10 24 electronic visual analogue scale (eVAS, Aalborg university, Aalborg, Denmark), where 0 indicated no 1 pain at all and 10 the worst pain possible. For the CPT at 2°C, participants were asked to immerse 2 their foot for five minutes and for the CPT at 7°C (7-9°C ± 0.1°C), seven minutes. If a participant could 3 not complete the CPT, the last value carried forward method was used for missing data of the 4 maximum and end pain. The time for each participant to reach their maximum pain from the cold 5 water was recorded. 6 7
PPT and potency of endogenous pain controls 8
The PPTs were measured using a hand held algometer with a circular probe of surface area 1 cm 2 9
(Algomed, Medoc, Ramat Yishai, Israel). Participants were given a switch to press as soon as they 10 started to feel pain from the pressure applied at the testing sites. The algometer was applied 11 perpendicularly to the sites, and pressure was gradually increased at a rate of 30KPa/s 67 until the 12 participant pressed on the switch. The average of two PPT readings at each site was recorded. 13
14
To measure the potency of endogenous pain controls, CPT was used as conditioning stimulus and 15 PPT as the testing stimulus. The parallel paradigm 63 was used. The change in PPT at the contralateral 16 wrist reflected the potency of CPM, while the change in PPT at the ipsilateral knee reflected the 17 potency of local inhibition. The PPTs were measured before and at two minutes after the start of the 18 CPTs. The assessor was blinded to the pain history and the pain adaptability status of the 19 participants. 20
Confounding factors 21
Thermal detection and pain thresholds 22
The cold and warm detection thresholds and cold and heat pain thresholds of the participants were 23 measured using the Thermal Sensory Analyser II (TSA-II, Medoc, Ramat Yishai, Israel) at all six sites. 24
Three consecutive cold or warm stimuli were applied using the method of limits (thermode size 1 30x30mm 2 ) starting from a baseline temperature of 32°C and a temperature returning rate of 4°C/s. 2
For the assessment of the cold and warm detection thresholds, the temperature was decreased or 3 increased at a rate of 1°C/s, with an inter-stimulus interval ranging from 3 to 5s 7,51 . The temperature 4 was changed at a rate of 3°C/s with an interval of 20s for the assessment of cold pain and heat pain 5 thresholds 24, 26 . The safety cut-off temperatures were set at 0°C and 50°C. For participants whose 6 pain thresholds were beyond this range, 0°C and 50°C were recorded as their cold and heat pain 7 thresholds respectively. 8 9
Pain catastrophizing 10
Pain catastrophizing scale (PSC), which is a validated questionnaire 46, 47 , was used to assess the 11 participants' feeling and thoughts when they were in pain 54 . Participants were asked to rate how 12 often they experienced the 13 thoughts and feelings listed when they were in pain. The total score 13 was calculated, a higher score indicates a higher extent of catastrophizing. 14
15
Level of depression, anxiety and stress 16
The Depression Anxiety and Stress Scale-21 items (DASS-21) 39 was used. This questionnaire, with 17 proven psychometric properties 8 , consists of three subscales, each containing seven items for 18 depression, anxiety and stress, respectively. Higher scores represent more severe depression, 19 anxiety or stress. 20
Functional status 21
A validated modified Roland Morris Questionnaire (RMQ) was used 30, 50 . This questionnaire contains 22 24 items of which participants chose those that applied to them. The total number of items chosen 23 was calculated; the greater the score, the more severe the disability 6, 30 . 24
Sleep quality 2
The sleep quality was measured using the validated questionnaire, Pittsburgh Sleep Quality Index 3 (PSQI) 9, 21, 41 . Participants were asked about their sleep pattern in the last month. A score of five or 4 less was associated with a good sleep quality, otherwise a score greater than five was associated 5
with poor sleep quality. 6 7
Skin and water temperatures 8
The skin temperature of the foot was recorded by taking thermal snapshots using an infrared 9 camera with 0.1°C accuracy (Testo 890, thermal imager, Testo, Germany) prior to the CPT. The 10 temperature of the foot to be immersed in the cold pressor was measured at the midpoint between 11 the tip of the middle toe and the anterior aspect of the ankle level with the malleoli. This point was 12 chosen as it was fully immersed in the cold pressor, and the malleoli are easily identified on thermal 13
images. The water temperature was measured using an external probe immersed in the water bath 14 (external probe, Thermo Scientific, USA). 15
16
Adverse events 17
The participants were monitored for any adverse events associated with CPT such as fainting, and 18 the frequency of adverse events were recorded. 19 20 Sample size calculation 21 It was hypothesised that the proportions of PA (39%) and PNA (61%) found in healthy participants 67 22 would be applicable to the MSK sample. Based on these proportions, with 80% power and 5% level 23 of significance (2-sided) a total of 42 participants were required. Considering that 15% of the 1 participants might not be able to complete the three sessions, we recruited 49 participants. 2 3 Data analysis 4 SPSS version 23.0 (IBM corporation, USA) was used for all analyses. The status of pain adaptability 5 was determined following the protocol from Zheng's study 67 . The strength of pain adaptability was 6 measured by subtracting the pain rating (to the cold water) at the end the CPT from the maximum 7 pain during the CPT. A decrease of two or more on a 0-10 pain scale from the maximum pain at the 8 end of CPT was categorised as PA; a decrease of less than two in pain was categorised as PNA. The 9 potency of CPM and local inhibition was assessed by calculating the percentage change in PPT 10 before and at two minutes after the start of the CPTs at the wrist and knee respectively. The 11 correlations of the experimental pain characteristics between the two CPTs were investigated using 12
Pearson correlation to assess the consistency of the measurements of the strength of pain 13 adaptability and potency of CPM across the two CPTs. Paired t-tests were used to compare the 14 strength of pain adaptability and potency of CPM assessed at the CPTs at 2°C and 7°C. The 15
proportions of PA and PNA, and the proportions of participants who completed and those who could 16 not complete the CPTs at 2°C and 7°C were compared using McNemar's chi square test. The baseline 17 characteristics, PPT and SUPRA of the PA and PNA were compared using independent t-tests and chi 18 square tests. Three-way (group, site and sides) mixed analysis of variance (ANOVA) with two 19 repeated measures (sites, 3 levels and sides, 2 levels) were used to analyse their cold detection 20 threshold, warm detection threshold, cold pain threshold and heat pain threshold. Mixed-design 21
ANOVAs with one repeated measures (time, 7 levels) were used to examine the change in daily 22 average pain, highest daily pain, daily hours in pain, and unpleasantness of pain over seven days in 23 PA and PNA. The correlations between the strength of pain adaptability and baseline clinical pain, 24 thermal pain thresholds and pressure pain thresholds were explored using Pearson correlations. The 25
Holm-Bonferroni adjustment was used for multiple comparisons 27 . The hypotheses were arranged in 1 ascending order according to their p-value, and the p-values were compared with the Holm-2 Bonferroni adjusted significance. A p-value that was smaller than the Holm-Bonferroni adjusted 3 significance was considered significant. The data in the text and tables are reported as mean and 4 standard deviation (SD) and in figures as mean and standard error of mean (SEM). 5 6
Results
7
Recruitment of MSK participants 8 Recruitment was between February 2015 and February 2016. After screening 138 individuals, 49 9 were eligible and were included in the study. Out of the 49 included participants, 25 participants 10 were chronic non-specific low back pain participants and 24 knee osteoarthritis participants (Fig 1) . 11
After the first session, the baseline measurements and thermal tests, six participants (five chronic 12 non-specific low back pain and one knee osteoarthritis) dropped out: four due to work or study 13 commitment, one for medical reasons and one for unknown reasons. Their data were excluded from 14 the analysis. 15 (Supplementary materials Tables S1-S5). Therefore, the data presented here are the combined data 21 of participants with chronic non-specific low back pain or knee osteoarthritis, with a total sample of 22 43 . All analyses were performed for the 43 MSK participants with a majority of them being male, 23 middle aged, overweight, and suffering from moderate pain with a pain history over seven years 1 (Table 1) 
CPT 2°C vs CPT 7°C
5
All 43 pain participants were tested with both CPTs (2°C and 7°C) in a random order. Pain induced by 6 the CPT at 2°C was moderately correlated with that induced at 7°C (average pain, r=0.53, p<0.01; 7 maximum pain, r=0.70, p<0.01) ( Table 2 ). There was a statistically significant difference in the 8 maximum pain between the two CPTs, however the difference was very small (0.54 ± 1.31). Strong 9 correlations were found in the time to reach maximum pain (r=0.77, p<0.01) and strength of pain 10 adaptability (r=0.74, p<0.01) between the two CPTs. PA and PNA were identified during both tests. 11
Out of the 43 participants 34 (79%) were consistent in their pain adaptability status, that is, they 12 were either PA or PNA for both CPTs. The remaining 21% (nine participants) were not consistent in 13 their pain adaptability status, meaning these participants were PA in one CPT and PNA in the other. 14 Although there were nine participants who were inconsistent in their pain adaptability status, there 15 was no significant difference in any measure between them and the rest of the participants. The 16
proportions of the PA and PNA, and those who completed the CPTs and those who could not were 17 not statistically different across the two CPTs either ( Since a strong correlation was shown between the strengths of pain adaptability across the two CPTs, 2 and the proportion of PA and PNA between the two CPTS did not differ, in the following sections, PA 3 and PNA identified using the CPT at 2°C will be used to explore the differences between PA and PNA. 4 5
Baseline characteristics 6
Among the 43 participants, 18 PA and 25 PNA were identified using a CPT at 2°C. No significant 7 difference was found between PA and PNA in their demographics, pain history, sleep quality, 8 function, quality of life and psychological factors (Table 3) . Similarly, no statistically significant 9 difference was observed between the PA and PNA in room temperature, water temperature or foot 10 temperature. There was a trend that PNA had more comorbidity than PA did (t 41 =-2.16, p=0.02), there 11 was however no statistically significant difference between the two groups (adjusted criterion of 12 statistical significance <0.01). 13 14 15
Pain adaptability and clinical pain 16
No significant correlations were found between the strength of pain adaptability and features of 17 clinical pain (daily average pain, highest pain, hours in pain, and unpleasantness of pain).No main 18 effect of group were observed for daily average pain, highest pain, hours in pain, and 19 unpleasantness of pain over a 7-day period. However, a statistically significant group by time 20 interaction for the unpleasantness over seven days (F (6,246) = 3.01, p = 0.01) was found (Fig 2) . The 21 unpleasantness reduced from 7.12 ±3.22 to 6.06 ±3.47 over 7 days in the PA group whereas it 22 oscillated and stayed relatively high in PNA group (from 9.04 ± 3.89 to 8.80 ± 2.78). 23
Pain adaptability and QST 2
Thermal and mechanical pain thresholds 3
The PPTs and SUPRAs of PA and PNA at all sites before the CPT showed no statistically significantly 4 difference between the two groups, although the PNA appeared to have lower PPTs than the PA 5 (Table 4 ). Mixed-design ANOVAs resulted in no main effect for groups in either the cold and warm 6 detection thresholds or their cold and heat pain thresholds at all sites (Table S6) . 7 8 Correlations between the strength of pain adaptability and baseline thermal detection and pain 9
thresholds and pressure pain thresholds were explored. Significant correlations between the 10 strength of pain adaptability and warm sensation threshold at the right knee (r = 0.37, p = 0.02) and 11
heat pain threshold at the left wrist (r = 0.045, p < 0.01) were observed. The higher the warm 12 detection threshold or heat pain threshold, the stronger the strength of pain adaptability was. 13
14
CPT induced pain 15
The analysis of the experimental pain parameters during the CPT showed no difference in the 16 average (p=0.43) and maximum (p=0.60) pain between PA and PNA ( Table 5 ). A statistically 17 significant difference was found between the PA and PNA in their time to reach maximum pain 18 during the CPT (Table 5) , with the PA (65.81 ± 31.54s) reaching their maximum pain faster than the 19 PNA (142.28 ± 133.63s). A significant difference was also observed in their pain difference (strength 20 of pain adaptability) between the maximum experimental pain and the experimental pain at the end 21 of the CPT ( Table 5 ). The PA had a higher pain difference (5.32 ± 1.96) than PNA (0.19 ± 0.47), which 22 is expected as it was based on this outcome measure that PA and PNA were categorized. The time 23 course for pain intensity from the CPT at 2°C is shown in Fig 3. 
Pain adaptability and potency of endogenous pain controls 4
There was no significant difference in the percentage PPT changes at the knee (t 41 =-1.04, p=0.30) 5 and wrist (t 41 =0.70, p=0.50) during the CPT between the PA and PNA, thus no difference between 6 the PA and PNA in their potency of either local inhibition or CPM. Further, no significant correlation 7 was found between the strength of pain adaptability and potency of local inhibition (r=0.04, p=0.79) 8 ( Fig S2) , and strength of pain adaptability and potency of CPM (r=0.23, p=0.14) ( Fig S3) . 9
Discussion (1499 words) 10 The dichotomy of PA and PNA exists in MSK participants. Both the CPTs at 2°C and at 7°C could be 11 used to identify PA and PNA. Pain adaptability was highly correlated between the two sessions. No 12 adverse events were observed. The time to reach the maximum experimental pain was shorter in 13 the PA than PNA. The PA, but not PNA, reported a gradual reduction in clinical pain unpleasantness 14 over seven days. The two groups did not differ in other measures. The strength of pain adaptability 15 and potency of CPM were not correlated, indicating potentially two forms of endogenous pain 16 controls were involved during the CPT. 17 18 Pain adaptability is reliable and is not temperature dependent 19 PA and PNA exist in healthy humans 15, 67 . This is the first study showing that this dichotomy also 20 exists in MSK individuals. Indeed, about 40% and 60% of PA and PNA individuals were identified in 21 the current study, which is agreement with previous studies in healthy participants, with the 22 proportions of PA and PNA being 39% and 61% respectively in one study 67 and 35% and 65% 23 respectively in another 15 . A similar proportion (31% PA, 69% PNA) was also found when a hot water 1 immersion at 47.5°C for five minutes was used in healthy participants 15 . This shows that pain 2 adaptability does not seem to be temperature dependent. 3 4 The pain adaptability status was inconsistent in 21% of participants between CPT at 2°C and 7°C. A 5 strong correlation of the strength of pain adaptability between the two sessions implies however 6 that status of pain adaptability is stable and can be reliably assessed. A previous healthy human 7 study 15 reported that 65% of the participants were consistent and 35% were not. 8
9
Both CPTs could also be used to induce CPM, although very weak. This can be explained by the 10 impaired CPM in MSK individuals 37 . The completion rates and the percentage differences in the 11 strength of pain adaptability and potency of CPM did not differ between the two CPTs. No adverse 12 events were reported, being consistent with previous CPT studies 18, 45 . Thus, two CPTs can be used to 13 assess both the strength of pain adaptability and potency of CPM, and are safe for MSK populations. 14 16 In the current study, CPT was used to assess both pain adaptability and potency of CPM. CPM is 17 usually transient or lasts the same duration as the conditioning stimulus 55 . However, some other 18 studies reported that CPM lasted after the conditioning stimulus terminated, and the duration 19 ranged from 5 minutes to one hour 19, 23, 36, 57 . One could argue that the decrease in pain rating at the 20 end of the CPT seen in the PA could be the effect of CPM. However, in the current study, the 21 potency of CPM in the PA did not differ from that in the PNA, and no significant correlation was 22 observed between the strength of pain adaptability and potency of CPM. Therefore, the status of 23 pain adaptability was not impacted by the potency of CPM. This observation is consistent with the healthy human study 67 . This shows that these two endogenous pain controls could operate through 1 different mechanisms. 2 3 CPM is the only QST assessing endogenous pain inhibition. Limited studies show that a poorer CPM 4 is related to increased number of pain sites 20 in MSK population, and its potency predicts the 5 outcomes of anti-depressants or surgery 16, 64, 65 . However, CPM and its association with pain are far 6 from clear. Inefficient CPM does not always lead to more severe pain. Patients with a longer 7 duration of pain history have a more efficient CPM than those with a shorter-pain history 22 . This 8 observation is resonated with other studies where even within chronic pain patients, the efficiency 9 levels of CPM varied 17 . Other forms of endogenous pain inhibition may contribute to those variations. 10
Pain adaptability is not associated with CPM
Pain adaptability could be one of them. 11
12
Clinical implications of pain adaptability 13 Consistent with the previous healthy human study 67 , the PA and PNA did not differ in any 14 demographic data, or QST. The only two significant differences were that the PA reached their 15 maximum pain faster than PNA did and reported a gradual reduction of pain unpleasantness over a 16 7-day period. It is likely the association between pain adaptability status and latency to the 17 maximum pain could be due to the time to process the nociceptive input from the noxious CPT and 18 to activate the descending inhibition. Such an inhibition is likely to be sustained in PA individuals 19 contributing to a continuous reduction of pain during the CPT, and a gradual reduction of pain 20 unpleasantness over seven days, which is in contrast to a fluctuation of pain unpleasantness in PNA. 21
This temporal aspect of pain and related inhibition is not assessed in the current QST paradigm. Yet 22 temporal characteristics of pain are important as illustrated in the following two examples. 23 1 participants, found a delayed report of maximum experimental pain in the older group 66 . Both 2 groups had similar pain ratings and flare response to topical capsaicin. However, there was a trend 3 that the older participants were slower in reaching their maximum experimental pain. Further, the 4 secondary hyperalgesia induced by capsaicin (area of punctate hyperalgesia) was maintained for a 5 significantly longer duration in the older than in the younger participants, and was not reversed by 6 local anaesthesia 66 . This means that the younger participants reached their maximum pain faster, 7
and also presented with pain inhibition sooner than the older participants. It was proposed that 8 those differences in the latency of reporting maximum pain and maintained hyperalgesia might be 9 due to reduced capacity of the central nervous system to activate the inhibition systems in the older 10 participants 66 . Similarly, the PNA could have a reduced capacity to activate the inhibitory systems, 11 hence the longer time to reach the maximum pain and the lack of pain inhibition during the CPT. 12
13
This lack of pain inhibition might impact on the capability of individuals to cope with a new episode 14 of pain. A recent study 28 followed up the day to day pain experience of post-surgical patients for 60 15 days and found significant individual variations in how post-operative pain was reduced and at which 16 time point. Significant pain reduction varied from day 10 to day 21 post-surgically, with some 17 patients presenting with a fast reduction whereas others a slow reduction. The authors commented 18 that currently there is no way to predict who would be in which category. Previous research shows 19 the potency of pre-surgical CPM may predict the severity of post-surgical pain. It is unknown if pre-20 surgical pain adaptability might help predict the time course of post-surgical pain. 21
22
Compared with PA, PNA tended to suffer from more comorbidities, which might interfere with this 23 activation-inhibition loop. A recent study on knee osteoarthritis identified a subgroup of patients with more comorbidities and more severe pain 33 , suggesting that comorbidity indeed could be 1 related to pain sensitivity and hence pain adaptability. However, this hypothesis should be debated 2 as pain adaptability was also identified in healthy participants without comorbidities 15, 67 .  3   4 Pain sensitivity and pain modulation are physiological responses that are influenced by psychological 5 behaviours 1, 12, 44, 59 and genetics and environment 43 . PA and PNA did not however differ in anxiety, 6 depression, stress and pain catastrophizing measured in the current study. Further studies exploring 7 the influence of psychological factors, such as suggestibility, coping strategies or expectations, are 8 needed. 9
Limitations
10
This study has a few limitations. Firstly, the sample size might not be large enough to achieve 11 statistical differences in some outcome measures. Using the PPT results at the wrists from the 12 current study with 80% power and α level of 0.05, the minimum required total sample size to 13 achieve significance was 84. Secondly, some participants could not complete the CPTs and did not 14 have a PPT measurement at the two minutes time point. Their PPT was considered unchanged at the 15 two minutes time point and thus the potency of their CPM could have been underestimated. 16 However, removing such participants from the analysis did not change the results. Lastly, two 17 participants reported a low level of pain rating to CPT and the rating did not change during the 18 whole test. They were categorized as PNA. It is possible that this lack of change might be another 19 form of adaptive behaviour. This could be the reason why not much difference was found between 20 the PA and PNA. However, when those participants were removed from the analysis, this did not 21 impact on the current findings. 22
Conclusions 1
The pain adaptive and pain non-adaptive exist in patients with chronic musculoskeletal pain. A cold 2 pressor test at either 2°C or 7°C is a reliable method to measure this form of inhibition. Pain 3 adaptability is dissociated with the potency of CPM; and could reflect the temporal aspect of pain 4 inhibition that is not explained by CPM. It would be important to replicate this study with less painful 5 stimuli than CPT, while controlling for psychological factors during the stimulation. The relevance of 6 pain adaptability in predicting the time course of post-operative pain and in treatment response 7 should be further explored. 8 9 10 Acknowledgements 11 We would like to thank Matthew Wong for his technical support, Samantha Harman for her help in 12 the enrolment of participants, and Thomas Graven-Nielsen for his comments on the data analysis. 13
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